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Background: Dengue disease is one of the most significant vector-borne illnesses in the world. The emergence
and re-emergence of dengue infections in many parts of the world affect millions annually and continue to burden
public health systems especially in low-income populations. Advances in dengue vaccine development showed
promising results; however, protection seems to be suboptimal. There is no licensed chemotherapeutic agent
against dengue to date. An ideal scenario of combinatorial vaccination of high-risk individuals and chemotherapy
of the diseased during outbreaks may compensate for the meager protection offered by the vaccine. The dengue
virus protease is important to viral replication and, as such, has been identified as a potential target for antivirals. It
is, therefore, our objective to establish and optimize an appropriate screening method for use during the early
stages of drug development for dengue.
Methods: In this study, we developed and optimized a biochemical assay system for use in screening compound
libraries against dengue virus protease. We tested the selected protease inhibitors with a cell-based assay to determine
inhibition of viral replication.
Results: We have presented direct plots of substrate kinetics data showing an apparent inhibition of the protease
at excessive substrate concentrations. The most common sources of interference that may have affected the said
observation were elucidated. Finally, a screen was done on an existing compound library using the developed
method. The compounds selected in this study showed inhibitory activity against both the recombinant dengue
protease and cell-based infectivity assays.
Conclusions: Our study shows the practicality of a customized biochemical assay to find possible inhibitors of
dengue viral protease during the initial stages of drug discovery.
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Dengue disease is a public health problem that continues
to affect approximately 100 countries globally with an
estimated 390 million cases per year of which majority
are children. The burden of disease lies mostly in the
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more people at risk [1]. Trans-ovarial transmission of
dengue virus (DENV) within mosquito populations can
facilitate transmission between or within epidemics, thus
complicating disease control strategies [2, 3]. Human
migration and vector invasiveness contributed to the
emergence and re-emergence of dengue in Europe and
Asia thus highlighting the need for a more proactive ap-
proach in dealing with this neglected disease [4, 5].
The causative agent, dengue virus, is a single-stranded
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DENV serotype is phylogenetically distinct, suggesting
that each could be considered as a separate virus. Trans-
mission is accomplished through the bite of mosquitoes,
prominently, Aedes aegypti and Aedes albopictus. In
humans, intrinsic incubation period ranges 3–10 days
after the bite of infected mosquitoes [6, 7]. Although
dengue infection is generally asymptomatic, it may result
in a wide spectrum of clinical disease, ranging from a
mild flu-like syndrome (dengue fever) to the most severe
forms of the disease, which are characterized by coagu-
lopathy, increased vascular fragility, and permeability
(dengue hemorrhagic fever). The latter may progress to
hypovolemic shock (dengue shock syndrome). Poor clin-
ical outcomes have been linked to secondary infections
[8]. However, not all heterologous secondary infections
cause subsequent severe forms of the disease. Host and
viral factors, age, and timing of infection are some of the
aspects to be considered [9].
The lack of chemotherapeutic agents and heavy reli-
ance on vector control complicate the management and
prevention of dengue. Although recent advances in vac-
cine development have proven that a tetravalent prepar-
ation is possible, field trials showed only around 50 %
vaccine efficacy and meager protection against specific
serotypes [10, 11]. One study estimates vaccine protec-
tion in a population from 24 to 54 % according to their
models [12]. This observation led to more questions re-
garding the mechanisms involving immunity against
dengue and proxy determinants of protection. The suc-
cess of marketed drugs targeting viral enzymes such as
in hepatitis C virus (HCV) and human immunodefi-
ciency virus (HIV) has directed the interest of re-
searchers towards flaviviral proteases. Recent literature
suggests that the viral proteins of DENV will probably
have a lower tendency to experience resistance-causing
mutations than in the case of HCV and therefore is suit-
able as potential drug targets [13].
The 11 kilobase DENV genome encodes a polyprotein
containing the structural and nonstructural (NS) pro-
teins. The polyprotein is processed by several proteases,
including that of the host. Similar with other flaviviruses,
the dengue virus protease is considered as a trypsin-like
serine protease located within NS3 [13]. The NS3 has
two enzymatic domains, a serine protease (NS3pro) and
helicase component located at the amino and carboxyl
terminals, respectively. Interestingly, DENV protease has
a marked cleavage site preference for dibasic residues
which is distinct from native trypsin [14]. The protease
domain requires the 40-amino acid central hydrophilic re-
gion of NS2B (NS2B(H)) as a cofactor which forms as part
of the substrate recognition region [13]. The NS2B(H)-
NS3 protease complex (NS2B(H)-NS3pro) is vital for the
post-translational processing of the polyprotein precursorand is essential for viral replication and maturation of in-
fectious virions [14]. Considering these points, the dengue
protease component located within NS3 is a very promis-
ing target for antiviral development. Hence, the present
study aims to establish and optimize an assay for use dur-
ing the early stages of drug development for dengue.
In this study, we have constructed and expressed a re-
combinant DENV2 viral protease for use in screening of
potential lead compounds. Our optimized biochemical
assay provided a straightforward and practical alternative
to currently available assay methodologies. Also, we have
shown and compared two enzyme kinetic models to
guide future researchers in analyzing their data. The
established assay identified potential lead compounds
which were confirmed by cell-based assays.
Methods
Cloning of pET28a/DENV NS2B(H)-G4SG4-NS3pro of
DENV2
The DENV NS2B(H)-NS3pro gene sequence containing
hydrophilic residues 49-96 of NS2B and N-terminal 180
amino acids of NS3 were amplified from DENV-2 16681
infectious clone (GenBank Accession: U87411) (given by
Richard Kinney, Center for Disease Control and Preven-
tion, Division of Vector-borne Diseases, Fort Collins,
CO, USA) analogous as described previously [15, 16].
Briefly, the primer pairs Nhe1-NS2B-F and (G4SG4)-
NS2B-R, (G4SG4)-NS3-F, and Xho1-NS3-R were used
during polymerase chain reaction (PCR) to produce the
fragments NS2B(H)-Linker and Linker-NS3pro, respect-
ively. Subsequently, overlapping PCR was performed
through the combination of both templates with primer
pairs Nhe1-NS2B-F and Xho1-NS3-R to produce the
final full length NS2B(H)-G4SG4-NS3pro incorporating
an overlapping region of 27 nucleotides and restriction
endonuclease recognition sites at both ends. The PCR
product was then digested with NheI and XhoI before
cloning into pET28a vector (Novagen) to yield the N-
terminal polyhistidine-tagged fusion protein. All PCR re-
actions were done using Phusion® High-Fidelity DNA
Polymerase (New England Biolabs). Construct sequence
was confirmed by automated Sanger sequencing using
BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems).
Expression and purification of DENV2 NS2B(H)-G4SG4-
NS3pro (rNS2B3pro)
The pET28a construct containing the DENV NS2B(H)-
G4SG4-NS3pro was transformed into BL21-CodonPlus
(DE3)-RIPL strain (Agilent) which provides correction for
possible codon usage bias. Cells were then grown in 250-
mL Luria-Bertani broth containing 50 μg/mL kanamycin
until OD600 reached 0.6–0.8. Protein expression was in-
duced by adding isopropyl β-D-1-thiogalactopyranoside
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37 °C. Cells were then harvested by centrifugation at 7000
rpm for 10 min at 4 °C and the cell pellet was resuspended
in 30-mL cold lysis buffer (phosphate-buffered saline)
prior to mechanical lysis by sonication on ice. The cell
suspension was then centrifuged at 15,000 rpm for 30 min
to separate the supernatant from the insoluble fraction.
The collected soluble fraction was then filtered through a
0.45-μm polyvinylidene fluoride (PVDF) syringe filter unit
(Merck-Millipore).
The filtrate containing the histidine-tagged fusion pro-
tein was subsequently purified using gravity flow immo-
bilized metal affinity chromatography (IMAC). Briefly,
Cobalt TALON® (Takara-Clontech, Japan) was loaded
into an open column to approximately 1-mL bed vol-
ume. The column was subsequently washed with 20 vol-
umes of distilled water prior to column equilibration
with another 20 volumes of lysis buffer. The previously
filtered sample was loaded then washed with 40-mL na-
tive wash buffer (20 mM imidazole in lysis buffer) to re-
move other contaminating proteins. Elution was started
upon addition of 5 mL each of 100, 200, 400, and
800 mM imidazole (Wako, Japan) suspended in lysis
buffer. The elution fractions were then combined in
pairs, 100 and 200 mM, 400 and 800 mM before con-
centrating by centrifugation using Amicon Ultra-15
(Merck-Millipore). The fraction was further purified
using Superdex® 75 (GE Life Sciences, Japan) gel filtra-
tion column with running buffer containing 50 mM
Tris-HCl (pH 8–9) and 100–300 mM NaCl with a flow
rate of 0.4 mL/min. Detection was done using 280 and
220 nm. The different fractions were visualized by
Coomassie-stained sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) gels and anti-
histidine Western blots to confirm the presence of the
target protein. Protein concentration was determined
using Direct Detect® infrared spectrometer (EMD Milli-
pore, USA).
Confirmation of target protein using SDS-PAGE and
immunoblotting (Western blot)
The different elution fractions were collected for the
detection of the target protein. Approximately 10 μL of
each fraction was loaded for SDS-PAGE analysis and
immunoblotting. In Western blotting, PVDF membrane
containing the transferred protein was blocked by
BlockAce solution (Dainippon Sumitomo Pharma,
Osaka, Japan) then treated with mouse anti-histidine
monoclonal antibody as primary antibody and sequen-
tially stained by horseradish peroxidase (HRP)-conju-
gated anti-mouse antibody as secondary antibody. The
HRP reaction was developed and measured via chemi-
luminescence using ImageQuant™ LAS 4000 (GE Life
Sciences, Japan) biomolecular imager.Validation of protease activity and optimization of assay
components
A standard amount of purified protease was added into
wells of a black, flat-bottom 96-well plate containing
assay buffer (200 mM Tris-HCl, 20 % glycerol, pH 9.5)
then mixed. Reaction was started upon the addition of
the substrate and was monitored via ARVO MX 1420
Multilabel Counter microplate reader (Perkin-Elmer, Japan)
after 30 min. Assays were done at room temperature with a
final volume of 100 μL.
A substrate assay was done by comparing five different
coumarin-based fluorogenic substrates used in other flavi-
virus protease studies [17–20]. Briefly, a single concentra-
tion (1000 μM) of the selected substrates was added
similarly as described above. Reactions were started with
the addition of purified recombinant protease (rNS2B3pro)
with a final concentration of 100 μg/mL.
It has been mentioned in other studies that glycerol af-
fects the stability of some proteins in suspension; there-
fore, assay buffer containing various concentrations of
glycerol was studied to determine the optimal level to be
used in the system [21]. The fluorogenic peptide sub-
strate Bz-nKRR-MCA (Peptides International) was used
to monitor enzyme activity.
An inhibitor control is needed to validate screening;
therefore, different concentrations of a protease inhibi-
tor, aprotinin, were added into wells containing 100 μg/
mL rNS2B3pro and mixed prior to addition of the sub-
strate, Bz-nKRR-MCA. Fluorescence emission was mon-
itored every 5 min for 1 h to determine its stability
under assay condition.
Substrate kinetics experiments were done using vari-
ous concentrations of Bz-nKRR-MCA (10–1000 μM)
which were mixed in wells containing an assay buffer.
Reaction was initiated upon the addition of purified
rNS2B3pro to a final concentration of 1 μg/mL. Sub-
strate hydrolysis was monitored for 30 min using ARVO
MX 1420 Multilabel Counter microplate reader (Perkin-
Elmer, Japan) at room temperature. To estimate sub-
strate kinetic values, the rates of reaction were plotted as




Cell viability was determined using CellTiter 96® Non-
Radioactive Cell Proliferation Assay (MTT) (Cat #G4000,
Promega) according to the manufacturer’s recommenda-
tions. Briefly, compounds were resuspended into appro-
priate concentrations using culture media (Minimum
Essential Medium with 2 % fetal calf serum) prior to
addition into wells containing Vero cells in confluence.
Formazan formation was detected according to protocol
after 72 h of incubation at 37 °C with 5 % CO2. Two
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vehicle control (1 % dimethyl sulfoxide (DMSO) in culture
media) to determine the compound maximum nontoxic
dose (MNTD).
Cell-based infectivity assays
Focus formation assays were done to determine the ef-
fect of the compound on viral infectivity. Cells were in-
fected in close analogy to the procedure mentioned
previously except that Vero cells were used instead [22].
Serial dilutions of the compound in culture medium
were mixed with dengue virus 2 isolated from patient
serum, 00-St-022 (GenBank Accession: KF744401.1)
then added into wells containing Vero cells. The plates
were then incubated at 37 °C with 5 % CO2 for 72 h
prior to detection of intracellular DENV antigens.
Antigen detection enzyme-linked immunosorbent assay
(ELISA)
ELISA was performed to quantitatively determine the
level of viral antigen secreted in culture fluid post-
treatment as previously described [22, 23]. Briefly, 96-
well microplates were coated with anti-flavivirus IgG
from purified pooled serum and then blocked with
BlockAce (Dainippon Sumitomo Pharma, Osaka, Japan)
in PBS. The 5-day post-infection culture fluids were
added, the plates washed, and HRP-conjugated mAb
12D11/7E8 was mixed into wells. The HRP reaction was
detected by adding o-phenylenediamine dihydrochloride
(OPD) substrate in the presence of 0.02 % hydrogen per-
oxide, for 30 min at room temperature, and stopped
with 1 N sulfuric acid prior to OD measurement at
492 nm.
Statistical analysis
Analyses were done using GraphPad Prism version 6.07
for Windows, GraphPad Software, La Jolla, California,
USA, www.graphpad.com. Estimation of parameters in-
cluding the 50 % inhibitory concentration (IC50) were
computed using the above-mentioned software with
terms comparable to the recommendations of the Inter-
national Union of Pharmacology Committee on Recep-
tor Nomenclature and Drug Classification [24, 25].
Statistical treatment of data is specified under each ana-
lyses with significance assigned at p < 0.05. All experi-
ments were done in duplicates at least twice unless
stated otherwise.
Results
Cloning, expression, and purification of recombinant
DENV2 NS2B3pro
The DENV2 NS2B(H)-G4SG4-NS3pro plasmid con-
struct included the hydrophilic residues 49-96 of NS2B
and N-terminal 180 amino acids of NS3 joined by aglycine linker (Fig. 1a) [26]. The construct sequence was
verified by automated sequencing (Sanger method) prior
to transformation into expression cells. The 28-kDa re-
combinant protease (rNS2B3pro) was purified using
cobalt immobilized metal affinity chromatography. Dif-
ferent elution fractions were collected and visualized by
Coomassie Brilliant Blue staining and anti-histidine im-
munoblotting. Anomalous migration patterns on SDS-
PAGE were observed as in the previous studies (Fig. 1b)
[18, 27, 28]. The 100 mM imidazole eluted fraction was
further concentrated into approximately 1 mL prior to
size exclusion chromatography. Further purification was
attempted using Superdex® 75 (GE Life Sciences, Japan)
gel filtration column (Additional file 1: Figure S1). Since
the HPLC result was comparable to the purity produced
by the crude open column IMAC, the latter method was
then utilized for the remainder of the study.
Development of the assay system
Assay conditions mentioned in literature were optimized
with emphasis on substrate and control inhibitor selec-
tion and additive concentration. Based on the peptide
sequence suggested by Li et al. as control, Additional file
1: Figure S2A shows the comparison of different flavi-
viral fluorogenic substrates at a fixed enzyme concentra-
tion as used in other protease studies [26, 27, 29, 30].
The peptide substrate with a sequence norleucine-
lysine-arginine-arginine (nKRR) was confirmed to have a
higher substrate cleavage activity than that produced by
substrates used in other dengue, West Nile, and Japanese
encephalitis virus protease assays. The difference in ac-
tivity produced between the protective groups, benzoyl
(Bz) and acetyl (Ac), also seems to be insignificant.
Different concentrations of glycerol were assayed
wherein 20 % was considered to be standard in other stud-
ies [29, 31, 32]. Truly, the difference in activity among the
0–60 % concentrations can be observed (Additional file 1:
Figure S2B) upon comparison against 20 % glycerol.
Assumption of a blank (no substrate) as 100 % inhib-
ition in a compound screen is suboptimal; therefore, a
control inhibitor is necessary for screening. Literature
search led to the selection of aprotinin for further exper-
iments [29]. Different concentrations of aprotinin were
mixed with the recombinant protease prior to fluores-
cence monitoring every 5 min for 1 h. Additional file 1:
Figure S3A shows that at 30 min, a minimum of 40 μM
aprotinin was able to inhibit protease activity comparable
to that of buffer only controls. The same concentration
was able to maintain inhibition up to 1 h (Additional file 1:
Figure S3B).
The Michaelis-Menten model requires certain as-
sumptions to be fulfilled for the accurate estimation of
kinetic parameters. Firstly, the reaction should be ob-
served at initial velocity conditions, wherein the amount
Fig. 1 Cloning, expression, and purification of recombinant DENV2 NS2B3pro. a Graphical representation of the recombinant protease construct.
The figure shows the amino acid positions of the cofactor (NS2BH) and protease complex (NS3pro) linked by a 9-amino acid glycine linker. Binding
locations of primers used in the study were indicated. b Detection of recombinant protease by Coomassie staining (left) and chemiluminescent
immunoblotting (right). M molecular weight marker, sup crude supernatant, ppt cell pellet, FT flow through. Increasing amounts of imidazole eluted
the target protein (28 kD) which migrated anomalously at around 37 kD. Both showed elution of the target protein at 100–200 mM imidazole
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version into the substrate. Figure 2 shows the kinetics of
the recombinant protease produced with increasing con-
centration of the fluorogenic substrate Bz-nKRR-MCA.
The protease seems to follow the ubiquitous Michaelis-
Menten model kinetics up to around 500 μM of the sub-
strate. However, further increase in the concentration of
the substrate led to a model similar to that of substrate
inhibition. To further validate the observation, elimin-
ation of other extraneous factors such as photodetector
saturation, fluorescence quenching, or inner filter effect
was necessary. Initially, a fluorophore standard assay was
done wherein free 7-amino-4-methylcoumarin (AMC)
(Sigma-Aldrich) was serially diluted, processed, and read
as mentioned above with the exception of enzymeaddition. Photodetector saturation was observed on con-
centrations at least ten times the maximum fluorescence
emitted by substrate cleavage experiments (data not
shown). Consequently, the free AMC concentration pro-
ducing half the maximal values on the standard AMC
assay was chosen for the validation assay (Fig. 3a). To
determine whether significant absorption of fluorescence
emitted by the liberated fluorophore occurred with in-
creasing concentrations of the substrate, simulation of
fluorophore release upon hydrolysis was done using free
AMC (~30 μM) added into wells containing the uncleaved
peptide substrate. Figure 3b shows that there is no signifi-
cant difference in the levels of fluorescence detected
among the groups suggesting that fluorophore quenching
by the peptide substrate is highly unlikely. Michaelis
Fig. 2 Substrate saturation assay. Fluorogenic substrate was serially diluted prior to addition of 1 μg/mL purified recombinant DENV2 NS2B3pro.
Baseline values at time 0 were subtracted. Two nonlinear regression models of enzyme kinetics were plotted; Michaelis-Menten model (black
dashed line) and substrate inhibition model (red line). Inset shows Lineweaver-Burk plot of the same. Error bars indicate standard deviation (SD)
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presented under Table 1. Results suggest that the model
accounting for substrate inhibition fits the data points re-
gardless of maximal substrate concentration.
Selection of compounds
The optimized protease screening system based on results
mentioned was employed as a duplicate, single concentra-
tion (50 μg/mL compound, 1 μg/mL purified protease)
assay. Inhibition of protease activity was monitored with
fluorogenic peptide substrate, 100 μM Bz-nKRR-MCA, at
30 min using ARVO MX 1420 Multilabel Counter micro-
plate reader (Perkin-Elmer, Japan). Compounds inhibiting
at least 85 % of the enzyme control reaction were selected
for further investigation. Approximately 500 compounds
were screened and three were chosen for further study.
Protease IC50 values of the three selected compounds
ranged from 5 to 14 μg/mL based on the conditions set
above (Table 2). Dose response curves plotting concentra-
tions from 50 μg/mL is shown in Fig. 4.
Cell viability assay
The three compounds were diluted with culture media
and added into wells containing Vero cells in confluence
prior to detection of formazan formation 72 h post treat-
ment. The results showed cytotoxicity of all compounds
at 30 μg/mL. However, there was no significant differ-
ence in the cell viability versus 1 % DMSO control with
10 μg/mL except for ASDN-10343 which showed mar-
ginal effect (Fig. 5a). Hence, further experiments were
done at concentrations starting 10 μg/mL which was
considered to be the maximum nontoxic dose (MNTD).Cell-based infectivity assays
The effect of the selected compounds on viral infectivity
was assessed via focus formation assay. Figure 5b demon-
strates the reduction in focus number by the compounds
compared to vehicle control (1 % DMSO in culture media).
Although the strength of inhibition varied by compound,
at least 50 % inhibition at 5 μg/mL minimum concentra-
tion was seen among the selected. Significant inhibition
was observed at all concentrations tested for ASDN-10321
and ASDN-10343. Qualitative inspection by microscopy of
cell growth during the experiments showed congruence
with the previous cell viability results (data not shown).
Antigen detection enzyme-linked immunosorbent assay
(ELISA)
The secretion of viral antigens into the culture fluid was
also assessed by employing ELISA. Surprisingly, ASDN-
10321 also demonstrated significant inhibition at all con-
centrations tested (Fig. 5c).
Discussion
The dengue virus protease is a known attractive target
for antiviral development. Inhibitors targeting viral pro-
teases have been gaining popularity after recent advances
in drug development for hepatitis C and human im-
munodeficiency viruses, to name a few [33].
Although DENV protease assays have been widely
mentioned in literature, it is imperative that the assay
conditions be checked and specifically fitted to our ob-
jectives. In this study, a biochemical assay for screening
of potential inhibitors against dengue protease has been
established. The developed assay has identified lead
Table 2 IC50 values of selected compounds. Best-fit values and
their respective 95 % confidence intervals are presented
IC50 (μg/mL) 95 % CI (μg/mL)
ASDN-10287 9.786 9.015 to 10.62
ASDN-10321 5.498 5.251 to 5.756
ASDN-10343 14.37 13.26 to 15.57
Determination of was IC50 done using nonlinear regression fitting
Fig. 3 Free fluorophore assay. a Serially diluted-free fluorophore
(AMC) was evaluated in similar conditions as with the protease assay
to determine photodetector saturation. The maximal fluorescence
value (approx. 150,000 units) elicited during cleavage conditions was
indicated with a dashed line. b Substrate titration assay. Different
concentrations of fluorogenic peptide Bz-nKRR-MCA were mixed
with 30 μM of free AMC and read after 30 min of incubation to
detect fluorescence quenching. Statistical analysis involved two-way
ANOVA with Bonferroni correction. Error bars indicate SD
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confirmed by cell-based infection assays.
We successfully cloned and expressed DENV2 viral
protease in Escherichia coli and were able to produce
the final product with adequate purity for use in an
assay. Different isolated peaks were seen during size ex-
clusion chromatography; nonetheless, their SDS-PAGE
profiles were similar (Additional file 1: Figure S1). A pre-
vious study suggested that this was possibly due to prod-
ucts of premature translation termination and/orTable 1 Michaelis constant (Km) approximation
Michaelis-Menten model
Max substrate conc. 1000 μM 500 μM




Adjusted R square 0.8965 0.9638
Estimates of Km derived from varied nonlinear regression models and substrate maexistence of aggregated recombinant protease species.
Nevertheless, they determined that the different peak
fractions did not differ in enzymatic activity [34].
Our study used direct plotting of kinetics data by non-
linear regression wherein estimation is straightforward. It
lacks certain disadvantages of linear kinetic plots such as
excessive effect of values at the lowest substrate concen-
trations. The substrate inhibition observed in our study
was consistent with the results of Tomlinson et al. using
West Nile and dengue viruses [17, 20, 35]. Our study used
a fluorogenic substrate based on the results of profiling
studies conducted by Li et al. which showed over 100-fold
improvement in activity compared to other existing se-
quences, including those used by Tomlinson [26]. Never-
theless, the inhibition was still observed. This may point
out that the length of the substrate and the amino acid se-
quence interacting with the P3/P4 positions of the enzyme
active site may have contributed to this observation. Al-
though the most common sources of possible interference
in our observation has been ruled out, other possibilities
such as insolubility of end product, intermediary product
formation, or pH changes upon substantial substrate
cleavage may lead into inefficient release or detection of
the fluorescent analyte. Thus, this observation needs to be
looked into more closely.
One of the drawbacks of having a standardized single-
point screening assay is that there is no account of differ-
ences in test compound characteristics. In our study, solu-
bility of some compounds in the aqueous buffer of the
protease system was a major difficulty. Visual inspection
of the compounds suspended in buffer was necessary to
ensure homogeneity during assays. Overtly insoluble com-
pounds were excluded from further analysis. The assay
system also suffered problems with autofluorescent com-
pounds which was also a limitation. The drawbacks en-
countered were not entirely new to drug screening [36–
38]. In a study by Simeonov et al., approximately 5 % ofSubstrate inhibition model







ximal concentrations at initial velocity conditions were presented
Fig. 4 Protease inhibition profile of selected compounds. Serial dilutions of compounds were mixed with 1 μg/mL purified recombinant DENV2
NS2B3pro prior to addition of 100 μM Bz-nKRR-MCA fluorogenic substrate and read after 30 min at 25 °C. Error bars indicate SD
Fig. 5 Cell-based assays. a Cell viability assay. Effect of compounds on cell viability was observed via the MTT assay. Results are expressed as
percentage of live cells relative to vehicle (1 % DMSO) control. b Cell-based infectivity assay of compounds. Selected compounds were examined
at different concentrations and evaluated for antiviral effect on Vero cells. Activity is reported as percentage relative to infected vehicle-treated
only control. c Antigen detection ELISA. Effect of the different compounds on the detected viral antigens in culture fluid was examined. Results
are expressed as percentage relative to infected vehicle-treated only control. Statistical analysis involved two-way ANOVA with Bonferroni correction.
Error bars indicate SD
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more fluorescent than 10 nM of their probe [39].
Recently, recombinant expression of uncoupled NS2B
cofactor and NS3 protease has been successful [40, 41]. In
vitro fluorescence-based protease assays showed minimal
differences between the characteristics of the unlinked and
glycine-linked constructs. The most prominent distinction
is the apparent lower substrate affinity of the linked con-
struct using longer peptide substrates. They suggested that
the linker may have reduced the flexibility of the protease
complex therefore restricting access to the active site [40].
This may explain the apparent inhibition observed in our
study wherein the excess substrate may have blocked the
entry to the site and that the limited flexibility reduced the
ability of the protease to form an “induced fit.” Neverthe-
less, the glycine-linked construct provides an adequate
model as target for small, active site inhibitors.
Conclusions
In this study, we described the successful development
of a dengue-2 protease biochemical assay as a useful tool
for screening of potential inhibitory compounds. Follow-
up experiments of selected compounds confirmed the
effects against dengue virus 2 replication in cells. The re-
sults will serve as basis for further modifications to the
lead compound structure so as to increase its activity
against dengue virus and improve its selectivity. Prelimin-
ary experiments are currently being undertaken to analogs
of the lead compounds as part of a structure–activity rela-
tionship study. An opportunity to test the same com-
pounds with other flaviviruses is under consideration.Additional file
Additional file 1: Table S1. Primers used in the amplification of the
target sequence. Lower case letters denote viral sequence; italicized
letters denote sequence comprising the glycine linker region. Letters in
bold indicate restriction endonuclease recognition sequences. Figure S1.
Fraction collections using size exclusion chromatography. (A) Absorbance
detected per each fraction as a function of time. (B) Coomassie SDS-PAGE
analysis, (C) anti-histidine Western blot. M = marker, W = 20 mM,
1 = 100 mM, 2 = 200 mM, 3 = 400 mM, 4 = 800 mM Imidazole. Figure S2A.
Comparison of different flaviviral protease substrates. Single concentration
of substrate (1000 μM) was added into wells containing a fixed amount of
DENV2 rNS2B3pro (100 μg/mL) and measured at 30 min. Figure shows
relative fluorescence compared to Bz-nKRR-MCA under the same conditions.
Error bars show standard deviation (SD). Figure S2B. Protease activity under
different glycerol concentrations. Relative protease activity compared to
20 % glycerol standard. Error bars indicate SD. Figure S3A. Inhibition of
protease activity by different aprotinin concentrations. Protease activity in
the presence of control inhibitor; aprotinin was shown as percentage of
enzyme only control. Concentrations ≤10 μM aprotinin significantly differ
from the blank (buffer only) at 100 μg/mL recombinant protease
concentration. Error bars indicate SD. Figure S3B. A fixed amount of
DENV protease was subjected to various concentrations of an inhibitor.
Aprotinin, showing trend over time. All sample reaction mixtures contain
100 μg/mL NS2B-NS3pro and 100 μM Bz-nKRR-MCA suspended in 200 mM
Tris-HCl with 20 % glycerol, pH 9.5, unless otherwise specified. Error bars
indicate standard deviation. (DOCX 1640 kb)Abbreviations
Ac, acetyl; AMC/MCA, 7-amino-4-methylcoumarin; Bz, benzoyl; DENV, dengue
virus; DMSO, dimethyl sulfoxide; HCV, hepatitis C virus; HIV, human
immunodeficiency virus; HRP, horseradish peroxidase; IC50, half maximal
inhibitory concentration; IMAC, immobilized metal affinity chromatography;
Km, Michaelis constant; MNTD, maximum nontoxic dose; MTT, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; nKRR, norleucine-lysine-
arginine-arginine; NS, nonstructural protein/s; OPD, o-phenylenediamine
dihydrochloride; PCR, polymerase chain reaction; PVDF, polyvinylidene fluoride;
SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis
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